{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T21:16:39Z","timestamp":1764364599859,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T00:00:00Z","timestamp":1656720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748"],"award-info":[{"award-number":["P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748","P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00262-022-03225-1","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T10:02:52Z","timestamp":1656756172000},"page":"183-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination"],"prefix":"10.1007","volume":"72","author":[{"given":"Ryan M.","family":"Kahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Govind","family":"Ragupathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin C.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Kravetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martee L.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Konner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,2]]},"reference":[{"key":"3225_CR1","doi-asserted-by":"publisher","first-page":"101042831771259","DOI":"10.1177\/1010428317712592","volume":"39","author":"Y Sun","year":"2017","unstructured":"Sun Y, Fan X, Zhang Q, Shi X, Xu G, Zou C (2017) Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1\/FGFR4 signaling. Tumour Biol 39:1010428317712592","journal-title":"Tumour Biol"},{"key":"3225_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41586-020-2850-3","volume":"587","author":"S Li","year":"2020","unstructured":"Li S, Liu M, Do MH, Chou C, Stamatiades EG, Nixon BG, Shi W, Zhang X, Li P, Gao S, Capistrano KJ, Xu H, Cheung NV (2020) Li MO (2020) Cancer immunotherapy via targeted TGF-\u03b2 signalling blockade in T(H) cells. Nature 587:121\u2013125","journal-title":"Nature"},{"key":"3225_CR3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jamaoncol.2018.2761","volume":"4","author":"RL Dood","year":"2018","unstructured":"Dood RL, Zhao Y, Armbruster SD, Coleman RL, Tworoger S, Sood AK, Baggerly KA (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519\u20131526","journal-title":"JAMA Oncol"},{"key":"3225_CR4","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","volume":"22","author":"M Markman","year":"2004","unstructured":"Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J (2004) Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120\u20133125","journal-title":"J Clin Oncol"},{"key":"3225_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1158\/1055-9965.EPI-09-0880","volume":"19","author":"KS Anderson","year":"2010","unstructured":"Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, Cramer D (2010) p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomark Prev 19:859\u2013868","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3225_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203\u2013213","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3225_CR7","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/annonc\/mdw084","volume":"27","author":"G Coukos","year":"2016","unstructured":"Coukos G, Tanyi J, Kandalaft LE (2016) Opportunities in immunotherapy of ovarian cancer. Ann Oncol 27(Suppl 1):i11\u2013i15","journal-title":"Ann Oncol"},{"key":"3225_CR8","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","volume":"13","author":"PJ Sabbatini","year":"2007","unstructured":"Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO (2007) Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 13:4170\u20134177","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3225_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2019.09.015","volume":"155","author":"RE O'Cearbhaill","year":"2019","unstructured":"O\u2019Cearbhaill RE, Deng W, Chen LM, Lucci JA 3rd, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ (2019) A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: an NRG Oncology\/GOG study. Gynecol Oncol 155(3):393\u2013399","journal-title":"Gynecol Oncol"},{"key":"3225_CR10","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","volume":"25","author":"RA Burger","year":"2007","unstructured":"Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165\u20135171","journal-title":"J Clin Oncol"},{"key":"3225_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the california, chicago, and princess margaret hospital phase II consortia. J Clin Oncol 26:76\u201382","journal-title":"J Clin Oncol"},{"key":"3225_CR12","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308","journal-title":"J Clin Oncol"},{"key":"3225_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2015.0070","volume":"13","author":"YL Li","year":"2016","unstructured":"Li YL, Zhao H, Ren XB (2016) Relationship of VEGF\/VEGFR with immune and cancer cells: Staggering or forward? Cancer Biol Med 13:206\u2013214","journal-title":"Cancer Biol Med"},{"key":"3225_CR14","doi-asserted-by":"publisher","unstructured":"Odunsi K. Immunotherapy in ovarian cancer (2017) Ann Oncol 28(suppl_8):viii1-viii7. doi: https:\/\/doi.org\/10.1093\/annonc\/mdx444","DOI":"10.1093\/annonc\/mdx444"},{"key":"3225_CR15","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. U.S. Department of health and human services (2009)"},{"key":"3225_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3225_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.2307\/2533060","volume":"52","author":"TJ Yao","year":"1996","unstructured":"Yao TJ, Begg CB, Livingston PO (1996) Optimal sample size for a series of pilot trials of new agents. Biometrics 52:992\u20131001","journal-title":"Biometrics"},{"key":"3225_CR18","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039\u20132045","journal-title":"J Clin Oncol"},{"key":"3225_CR19","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.4161\/cbt.6.12.4976","volume":"6","author":"D Matei","year":"2007","unstructured":"Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW (2007) PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6:1951\u20131959","journal-title":"Cancer Biol Ther"},{"key":"3225_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2012.04.013","volume":"59","author":"Y Wang","year":"2012","unstructured":"Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY (2012) Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine 59:145\u2013155","journal-title":"Cytokine"},{"key":"3225_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13048-017-0305-8","volume":"10","author":"T Pochechueva","year":"2017","unstructured":"Pochechueva T, Alam S, Sch\u00f6tzau A, Chinarev A, Bovin NV, Hacker NF, Jacob F, Heinzelmann-Schwarz V (2017) Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients. J Ovarian Res 10:8","journal-title":"J Ovarian Res"},{"key":"3225_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.31768\/2312-8852.2016.38(2):117-121","volume":"38","author":"EP Smorodin","year":"2016","unstructured":"Smorodin EP, Sergeyev BL (2016) The level of IgG antibodies reactive to TF, Tn and alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival. Exp Oncol 38:117\u2013121","journal-title":"Exp Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03225-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:05:27Z","timestamp":1672833927000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["3225"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03225-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2022,7,2]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.A. reports personal fees from Tesaro, personal fees from Immunogen, grants and personal fees from Clovis, grants from Genentech, grants from AbbVie, grants from Astra Zeneca, personal fees from Eisai\/Merck, personal fees from Mersana Therapeutics, personal fees from Roche\/Genentech, personal fees from Abbvie, personal fees from AstraZeneca\/Merck, personal fees from Repare, outside the submitted work. M.L.H. reports other from Sanofi, other from GSK, personal fees from Research to Practice, personal fees from Up to Date, other from Bayer, personal fees from GOG Foundation, personal fees from Tesaro, personal fees from Lilly Oncology, personal fees from Merck, personal fees from Janssen, outside the submitted work. A.I. reports personal fees from Mylan, outside the submitted work. V.M. reports grants from Eisai, grants from Merck, grants from Takeda, grants\u00a0from ArQule, grants from Karyopharm, grants from AstraZeneca, grants from Lilly, other from Clovis, other from Novasris, other from GSK, other from ITEOS, outside the submitted work. R.E.O. reports personal fees from Tesaro\/GSK, personal fees from Regeneron, personal fees from Seattle Genetics, other from AstraZeneca Pharmaceuticals, personal fees from Fresenius Kabi, personal fees from Gynecologic Oncology Foundation, personal fees from Bayer, personal fees from Curio, advisor for Carina Biotech, outside the submitted work; and non-compensated steering committee member for the PRIMA, Moonstone (Tesaro\/GSK), ARTISTRY7 (Arkemes) and DUO-O (AstraZeneca) studies. Her institute receives funding for clinical research from Bayer\/Celgene\/Juno, Tesaro\/GSK, Ludwig Cancer Institute, Abbvie\/StemCentrx, Merck, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab\/Seagen Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, Gynecologic Oncology Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}